# Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

> **NCT00307931** · PHASE3 · TERMINATED · sponsor: **UCB Pharma** · enrollment: 16 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Certolizumab pegol

## Key facts

- **NCT ID:** NCT00307931
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study was terminated early because of slow recruitment
- **Last updated:** 2011-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00307931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00307931, "Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00307931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*